These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 33253437)

  • 21. Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane.
    Nichols AL; Blumenfeld Z; Luebbert L; Knox HJ; Muthusamy AK; Marvin JS; Kim CH; Grant SN; Walton DP; Cohen BN; Hammar R; Looger L; Artursson P; Dougherty DA; Lester HA
    J Neurosci; 2023 Mar; 43(13):2222-2241. PubMed ID: 36868853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrovascular, Cardiovascular, and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors: A Propensity Score-Matched Population-Based Study.
    Leong C; Alessi-Severini S; Enns MW; Nie Y; Sareen J; Bolton J; Prior HJ; Chateau D
    J Clin Psychopharmacol; 2017 Jun; 37(3):332-340. PubMed ID: 28383363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of abnormal uterine bleeding associated with high-affinity compared with low-affinity serotonin and norepinephrine reuptake inhibitors.
    Engler J; Filliter C; Montastruc F; Abenhaim H; Rej S; Renoux C
    J Affect Disord; 2024 Apr; 350():813-821. PubMed ID: 38246277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents.
    Strawn JR; Mills JA; Poweleit EA; Ramsey LB; Croarkin PE
    Pharmacotherapy; 2023 Jul; 43(7):675-690. PubMed ID: 36651686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Escitalopram for treatment of major depressive disorder in adults].
    Llorca PM; Brousse G; Schwan R
    Encephale; 2005; 31(4 Pt 1):490-501. PubMed ID: 16389716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical implications of selective serotonin reuptake inhibitors-selective serotonin norepinephrine reuptake inhibitors pharmacogenetics during pregnancy and lactation.
    Koren G; Ornoy A
    Pharmacogenomics; 2018 Sep; 19(14):1139-1145. PubMed ID: 30105921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence.
    Womersley K; Ripullone K; Agius M
    Psychiatr Danub; 2017 Sep; 29(Suppl 3):629-644. PubMed ID: 28953843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
    Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
    CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
    van Harten J
    Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors as adjuncts for postoperative pain management: systematic review and meta-analysis of randomised controlled trials.
    Wang L; Tobe J; Au E; Tran C; Jomy J; Oparin Y; Couban RJ; Paul J
    Br J Anaesth; 2022 Jan; 128(1):118-134. PubMed ID: 34756632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of QT prolongation with serotonin reuptake inhibitors.
    Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
    Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.
    Owens MJ; Knight DL; Nemeroff CB
    Biol Psychiatry; 2001 Sep; 50(5):345-50. PubMed ID: 11543737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells.
    Kuwahara J; Yamada T; Egashira N; Ueda M; Zukeyama N; Ushio S; Masuda S
    Biol Pharm Bull; 2015; 38(9):1410-4. PubMed ID: 26328498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitors and epidemiological characteristics associated with prenatal diagnosis of congenital heart disease.
    Melov SJ; Shetty PS; Pasupathy D; Kirby A; Sholler GF; Winlaw DS; Alahakoon TI
    Prenat Diagn; 2021 Jan; 41(1):35-42. PubMed ID: 33067884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of in-utero exposure to selective serotonin reuptake inhibitors and venlafaxine on term and preterm infants.
    Hogue AN; Temple-Cooper ME; Lagzdins M; Worley S; Scwersenski J; Floyd R; Saker F
    J Neonatal Perinatal Med; 2017; 10(4):371-380. PubMed ID: 29286926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.